GlassScriptPhysician profile
Rachel Lee Doerr
NPI 1891070371
$6,078.85
in general payments reported to CMS, 2019-2025
33 companies · $2,088 in 2025
The $2,088 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $643 · 2022: $1,293 · 2023: $850 · 2024: $1,205 · 2025: $2,088.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,355 · Travel and Lodging: $788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,354.76 |
| Travel and Lodging | $788.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $1,293.62 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Astrazeneca Pharmaceuticals LP | $756.48 | 2021-2025 | Saphnelo, Airsupra |
| Teva Pharmaceuticals USA, INC. | $687.72 | 2022-2025 | Austedo Xr, Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $382.43 | 2021-2024 | Jardiance |
| Abbott Laboratories | $340.51 | 2021-2025 | Cardiomems, Triclip, Mitraclip |
| Glaxosmithkline, LLC. | $264.80 | 2023 | Arexvy |
| Organogenesis INC. | $260.49 | 2022-2025 | Apligraf, Affinity |
| Boston Scientific Corporation | $198.46 | 2021-2022 | |
| Aimmune Therapeutics, INC. | $192.52 | 2024-2025 | Zenpep |
| Amgen INC. | $158.07 | 2021-2024 | Uplizna |
| Solventum Corporation | $146.67 | 2024 | Prevena, Activ.A.C., Snap |
| Abbvie INC. | $125.00 | 2022 | |
| Axsome Therapeutics, INC. | $124.59 | 2025 | Auvelity |
| Mimedx Group, INC. | $115.61 | 2024-2025 | |
| Nevro Corp. | $104.18 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $103.90 | 2025 | Tremfya |
| Springworks Therapeutics, INC. | $103.53 | 2025 | Gomekli |
| Tg Therapeutics, INC. | $98.52 | 2024 | |
| Scynexis, INC. | $96.34 | 2022 | |
| Kci USA, INC. | $94.73 | 2023 | Activ.A.C. |
| Angiodynamics, INC. | $88.75 | 2022 | |
| Smith+Nephew, INC. | $66.71 | 2023-2024 | Collagenase Santyl |
| Sanofi-Aventis U.S. LLC | $51.31 | 2021 | |
| Pfizer INC. | $42.03 | 2025 | |
| Merck Sharp & Dohme LLC | $35.14 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $30.89 | 2021 | |
| Bardy Diagnostics, INC. | $30.00 | 2021 | |
| Medicure Pharma INC. | $28.33 | 2021 | |
| Astellas Pharma US INC | $15.87 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.35 | 2021 | |
| Amarin Pharma, INC. | $13.26 | 2021 | |
| Lifenet Health | $8.09 | 2025 | Theragenesis Wound Matrix |
| Ets Wound Care LLC | $6.95 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Doerr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.